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Highlights: 
 Mice with a human immune system (HIS mice) support lymphotropic virus infection. 
 Viral pathologies, including oncogenesis, can be recapitulated in HIS mice. 
 Primarily cell-mediated immune responses can be observed in HIS mice. 
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Abstract 
Pathogenic viruses are often difficult to study due to their exclusive tropism for humans. The 
development of mice with human immune system components opens the possibility to study 
those human pathogens with a tropism for the human hematopoietic lineage in vivo. These 
include HCMV, EBV, KSHV, HIV, HTLV-1, dengue virus and JC virus. Furthermore, some 
human pathogens, like HSV-2, adenovirus, HCV, HBV and influenza A virus, with an additional 
tropism for somatic mouse tissues or for additional transplanted human tissues, mainly liver, 
have been explored in these models. The cellular tropism of these viruses, their associated 
diseases and primarily cell-mediated immune responses to these viral infections will be 
discussed in this review. Already some exciting information has been gained from these novel 
chimeric in vivo models and future avenues to gain more insights into the pathology, but also 
potential therapies, will be outlined. Although the respective in vivo models of human immune 
responses can still be significantly improved, they already provide preclinical systems for in vivo 
studies of important viral pathogens of humans.  
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1. Mice with reconstituted human immune system components as models of human 
immune responses 
Human immune responses can be studied in a correlative fashion in only a few tissues, which 
can be biopsied from patients or healthy individuals, including peripheral blood, some secondary 
lymphoid tissues, like tonsils, and the tumor microenvironment, assessing tumor infiltrating 
lymphocytes (TILs). For a more systematic analysis and in order to study the outcome of 
manipulations during immune responses, immunologists have primarily turned to the mouse as 
an in vivo animal model of mammalian immune responses. However, with a more and more 
detailed analysis of the mouse immune system it has become apparent that significant 
differences in immune responses of the two species have developed during the 60 to 70 million 
years of divergent evolution of mouse and man [1]. Indeed after completion of both mouse and 
man genome sequencing the immune system was identified after olfaction and reproduction as 
the third most divergent organ system between the two species [2]. Among the eight distinct 
domains containing protein families with the highest rate of non-synonymous mutations between 
mouse and man 6 represented immunity related molecules accounting for more than 800 genes 
with chemokines being among the most diverse. Furthermore, among the 25 gene clusters that 
had undergone differential expansions 5 were again immunity related genes, including the non-
classical major histocompatibility complex (MHC) class Ib genes. These data indicate that the 
respective immune systems of mouse and man have been adjusted to their particular ecological 
niches and pathological challenges during evolution, and differ significantly in their immune 
responses. 
 One such group of inflammatory responses are burns, trauma and endotoxemia [3]. In 
comparing different mouse models for these diseases with patients, it was found that these 
conditions evoked immune responses with more similarities among patients than between 
patients and mouse models. Furthermore, the mouse models differed significantly in their gene 
expression among each other and were not predictive for the human responses. From these 
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studies the authors suggested to perform more clinical studies and develop new mouse models, 
which recapitulate human immune responses more closely. 
   One approach in this direction are mice with transferred or reconstituted human immune 
system components [4-7]. These are predominantly based on mouse strains, which lack murine 
lymphocyte development due to genetic lesions. The most popular strains are NOD-scid c
tm1Wjl 
(NSG), NOD-scid c
tm1sug (NOG), NOD Rag1-/- c
tm1Wjl (NRG) and BALB/c Rag2-/- c
tm1sug (BRG) 
mice. While NSG and NRG lack the common gamma chain (c) for interleukin 2, 4, 7, 9, 15 and 
21 entirely, NOG and BRG mice carry a truncated version that still allows cytokine receptor 
assembly. These assembled cytokine receptors might be able to serve as cytokine sinks in the 
respective mouse strains and thereby deprive the developing human cells of the affected 
cytokines. Human peripheral blood mononuclear cell (PBMC) transfer into these mice was 
initially used to study human immune system components in vivo. However, transplantation of 
fully differentiated human leucocytes leads to rapid graft-versus-host disease (GvHD), during 
which the incoming human immune cells attack the mouse host in a xenoreactive immune 
response. In contrast, for the reconstitution of human immune system components these mice 
receive human CD34+ hematopoietic progenitor cells (HPCs) (Figure 1), which reconstitute at 
least in the NOD background around 60% of human hematopoietic cells in peripheral blood 
during three months. The reconstituted cells contain human lymphoid and myeloid 
compartments, including 50% B cells, 40% T cells, 5% natural killer (NK) cells, 3% monocytes 
and 2% dendritic cells. Within the T cell compartment 70-80% are CD4+ helper T cells, while 20-
30% are CD8+ cytotoxic T cells. These average reconstitution frequencies can considerably vary 
from donor to donor and even within reconstituted mouse cohorts. Moreover, B cell 
reconstitution exceeds the frequency of human adult peripheral blood fivefold, while monocyte, T 
and NK cell development leads to three-, two- and twofold lower frequencies at three months 
after HPC transfer, respectively. In the BLT (bone marrow, liver and thymus) mice an organoid of 
human fetal liver and fetal thymus is in addition implanted to support human T cell education [8]. 
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Furthermore, this human organoid even allows good reconstitution in NOD-scid mice without the 
innate lymphocyte compromising c deletion and, thereby, allows for secondary lymphoid tissue 
anlage development, including mucosal reconstitution [9]. In contrast, BRG mice are usually less 
well reconstituted with human immune system components, often reaching only 10% of human 
hematopoietic cells in the peripheral blood after 3 months [10,11]. Xenoreactivity of the mouse 
myeloid compartment against the engrafting human cells was identified as the limiting factor. 
The inhibitory receptor SIRPengaging CD47 and cross-reacting with human CD47 only in the 
NOD background, was found to be responsible for this difference between the BALB/c and NOD 
mouse background [12]. Indeed transgenic or congenic expression of either the human or the 
NOD SIRP[10,11], or mouse CD47 gene transfer into reconstituting human hematopoietic cells 
[11] allows for as efficient human immune system component reconstitution in the BALB/c as in 
the NOD mouse background. Furthermore, a recent study used human SIRP bacterial artificial 
chromosome transgenic mice with additional knock-in of the four human cytokines M-CSF, IL-3, 
GM-CSF and TPO [13]. These MISTRG mice developed myeloid and NK cells more efficiently 
than NSG mice, but still a significant variation in human immune system component 
reconstitution could be observed. However, percentages of immune system components even 
vary between human individuals and the functionality of these is much more important for 
immunity against pathogens. Therefore, this review will concentrate on the immune responses 
that can be elicited in mice with reconstituted human immune system components (collectively 
called HIS mice) after infections with viruses. 
 
2. DNA virus infections 
2.1. Herpesvirus infections (HSV, HCMV, EBV, KSHV) 
Herpesviruses are a group of persistent pathogens that can alternate between latency for 
persistence and periodic lytic replication for spreading within the infected host and transmission 
to other hosts. They have co-evolved with their hosts during evolution and therefore even closely 
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related human and rodent viruses are significantly different [14,15]. Herpesviruses can be 
divided into -, - and -subgroups, and viruses of all these have been explored in HIS mice. 
 Herpes simplex viruses (HSV) are -herpesviruses and establish usually latency in 
peripheral neurons, from which they periodically reactivate and form genital and labial blisters. 
HSV-2 infection has been explored in HIS mice. Intravaginal infection with HSV2 was found to 
elicit lymphocyte infiltration at the site of infection in huBRG mice [16]. Moreover, HSV-2 specific 
T cells were detected at the infection site and in draining secondary lymphoid tissues. 
Furthermore, some IgG responses to HSV-2 were reported and, eliciting adaptive immunity by 
vaccination prior to HSV-2 infection, lowered viral titers after infection. These studies suggested 
that HIS mice can respond to HSV-2 infection by innate and adaptive immune responses, which 
in part are specific for this virus and seem to control infection. However, in these studies it 
remained unclear which murine and human cells were infected and how the human leucocytes 
were able to immune survey mouse tissues and controlled HSV2 within these. 
 Among the -herpesviruses, human cytomegalovirus (HCMV) infection was explored in 
huNSG mice [17]. In a first study HCMV was found to infect the reconstituted human myeloid 
compartment and could be reactivated from it by G-CSF treatment. However, initial infection was 
performed in this study by adoptive transfer of HCMV infected fibroblasts into the peritoneal 
cavity of huNSG mice. Therefore, in a follow-up study NSG mice were reconstituted with 
mobilized human adult CD34+ HPCs from either 3 HCMV positive or 1 negative donor [18].  
HCMV infection could be transferred into huNSG mice with hematopoietic stem cells of HCMV 
positive, but not negative donors. From both studies the authors suggested that G-CSF 
mobilization of HPCs in adult patients for transplantation could mobilize HCMV and increase the 
risk of diseases that are associated with this virus in the respective immunosuppressed patient 
population. 
 Finally, both human -herpesviruses have been tested in HIS mice [19]. The 1-
lymphocryptovirus Epstein Barr virus (EBV) was the first pathogenic challenge that was used in 
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HIS mice [20]. EBV establishes latent infection in human B cells and is associated with B cell 
lymphomas as well as epithelial carcinomas in patients [21]. In order to do so the virus 
capitalizes on the physiological differentiation of B cells, while infection of epithelial cells in vivo 
is much less well understood. While the expression of all eight EBV latency gene products 
(latency III) can be found in naïve B cells in humans [22], germinal center B cells carry primarily 
the reduced latency II program with expression of EBV nuclear antigen 1 (EBNA1), latency 
membrane proteins (LMPs) 1 and 2, as well as the non-translated RNAs, including EBV 
encoded small RNAs (EBERs) and micro RNAs. It is thought that EBV uses these different 
latency programs in order to push infected B cells towards memory cell differentiation [23], which 
constitutes the site of long-term EBV persistence [24]. Upon cognate antigen recognition via 
their B cell receptor and plasma cell differentiation, EBV reactivates from infected B cells into the 
lytic program, which then expresses more than 80 gene products to form virus particles [25]. Of 
these EBV infection programs, mainly latency III and lytic replication, can be accessed in HIS 
mice, and B cells are the main, if not exclusive cell type that harbors EBV after infection [26]. 
Furthermore the tumors that develop at increased frequencies after T or NK cell depletion are 
primarily lymphoproliferative lesions of EBV latency III expressing B cells, which can be cultured 
as lymphoblastoid cell lines (LCLs) in vitro [26,27]. These tumors can develop in secondary 
lymphoid tissues like spleen and mesenteric lymph nodes or at extra-lymphoid sites like liver and 
kidneys. Irrespective of their location, they are usually heavily infiltrated with T cells, and 
polyclonal or oligoclonal in nature [27]. However, loss of immune control allows more frequently 
the outgrowth of more aggressive monoclonal tumor cells. These EBV latency III infected cells 
constitute the majority of the EBV infected B cells in mice after infection with the B95-8 EBV 
strain, which was originally isolated from an American patient with symptomatic primary 
infection. The lymphocyte infiltrates are significantly reduced during infection with a B95-8 strain 
that lacks the latency III gene product EBNA3B [28]. These tumors then histologically resemble 
diffuse large B cell lymphomas (DLBCL) and a subset of DLBCL in human patients harbor EBV 
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with loss-of-EBNA3B-expression mutations. Apart from EBNA3B, however, they express the rest 
of the EBV latency III program. The difference in lymphocyte infiltration is in part due to the 
failure of mutant EBV transformed B cells to express the chemokine CXCL10, which attracts 
lymphocytes to the tumor microenvironment [28]. In addition to EBV latency III cells, a smaller 
subset of infected cells spontaneously enters lytic infection, and the frequency of these cells is 
also elevated after T and NK cell depletion [26,27]. The frequency of these lytically EBV infected 
B cells also increases after infection with another EBV strain, called M81 and isolated from an 
Chinese patient with EBV associated nasopharyngeal carcinoma [29]. Both early and late lytic 
EBV antigen products are expressed in these reactivating B cells [27,29]. In addition, several 
groups have reported that lower EBV latencies can be also observed in HIS mice. Histologically, 
both latency I and II have been observed [30-32]. However, lack of EBV antigen expression can 
be sometimes difficult to ascertain by immunohistochemistry. For example LMP1 expression is 
cycling in LCLs and only one third of these EBV latency III expressing B cells are positive for 
LMP1 protein at any given time point [33]. In an attempt to search for these lower EBV latencies 
with a different approach Heuts, Nagy, Klein and colleagues have recently reported Q promotor 
usage for EBNA1 expression in infected HIS mice [34]. EBNA1 is transcribed into a long mRNA 
also encoding other EBNAs during latency III, but utilizes its Q promotor for transcription during 
latency I and II. This Q promotor usage was dependent on CD4+ T cells, suggesting that 
follicular helper T cells might allow EBV infected B cells to access lower EBV latencies during 
low levels of germinal center reactions in HIS mice. Therefore, EBV infection of HIS mice might 
primarily cause latency III, but also allow low levels of lytic virus replication and maybe even 
EBV latencies I and II, which cannot be modelled by in vitro B cell infection with EBV. In addition 
to these EBV associated lymphoproliferations also immunopathologies have been observed 
after EBV infection in HIS mice. These include hemophagocytic lymphohistiocytosis and erosive 
arthritis [35,36]. In these studies, the Akata strain of EBV, which was originally isolated from a 
Japanese patient with Burkitt’s lymphoma, was used. If these EBV associated disease 
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manifestations, however, resulted from this strain variation, higher initial infectious doses or 
prolonged infection periods requires additional investigations. Nevertheless, EBV associated 
malignancies seem to be not the only EBV associated diseases that can be modelled in HIS 
mice.    
 In contrast to the extensive literature on EBV infection, the human 2-herpesvirus Kaposi 
Sarcoma associated herpesvirus (KSHV) has been much less explored in HIS mice. This virus is 
also associated with B cell lymphomas and the endothelial malignancy Kaposi sarcoma in 
humans [37]. An early report suggested that KSHV can establish persistent infection in NOD-
scid mice [38]. This seemed independent of human immune component reconstitution and be 
supported by various murine leucocyte lineages. However, a more recent study suggested that 
KSHV infection without human lymphocyte reconstitution is minimal [39]. In this later study 
KSHV infection was primarily contained in human B cells, but could only be maintained by 
biweekly KSHV injection into BLT mice. Furthermore, no KSHV associated pathology was 
reported in infected HIS mice. Thus, persistent KSHV infection and virus associated 
malignancies are still difficult to achieve in HIS mice. 
 Nevertheless, HIS mice constitute an extremely valuable in vivo system to study human 
herpesvirus infections, which are so exquisitely adapted to their human host. 
 
2.2. Adenovirus infections (Adenovirus) 
In the above discussed studies only the HSV infection probably involves both human and mouse 
cells in HIS mice. Therefore, hepatotropic adenovirus infection was explored to investigate the 
extent, to which the reconstituted human immune system components can survey infections of 
mouse somatic tissues [40]. These non-enveloped viruses, of which seven species and more 
than fifty types exist in humans, cause usually upper respiratory tract infection. While the 
adenovirus tropism differs in mice, it was found that T cells contribute to the immune control of 
adenovirus in the liver in HLA transgenic mice. These data suggest that human immune 
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responses to pathogens with tropism for mouse tissues can also be studied in HIS mice to a 
certain degree.  
 
2.3. Hepadnavirus infections (hepatitis B virus) 
While the immune control of adenovirus infection in HIS mice relied on the cross-talk between 
the human hematopoietic lineage and mouse liver cells, hepatitis B virus (HBV) infection 
requires in addition reconstitution of human hepatocytes. In such a model of human immune 
system and liver reconstitution persistent HBV infection could recently be established [41]. In 
humans, HBV causes liver inflammation, fibrosis and due to chronic immune stimulation 
hepatocellular carcinoma. Some of these pathologies could be recapitulated in HIS mice. HBV 
infection elicited human immune responses, liver inflammation and liver fibrosis, which in part 
was driven by M2 polarized human macrophages. Thus HIS mice with human hepatocyte 
reconstitution can reproduce some features of HBV infection and immunopathology. 
 
3. RNA virus infections 
3.1. Retrovirus infections (HIV, HTLV-1) 
So far HIS mice have been most often studied in the context of human immunodeficiency virus 
(HIV) infection, a lentivirus that depletes its main host cell, CD4+ T cells, during chronic infection, 
resulting in the acquired immunodeficiency syndrome (AIDS). In fact the respective literature is 
so extensive that its discussion goes beyond the scope of this review. Moreover, it has been 
summarized recently in eight reviews in the Journal of Infectious Diseases [42]. Therefore, I will 
just concentrate on some high-lights from the studies of HIV infection in HIS mice. Both CCR5- 
and CXCR4-tropic HIV-1 strains have been found to replicate in HIS mice and cause CD4+ T cell 
depletion  [43,44]. To some extent, especially BLT mice on the NOD-scid background also allow 
rectal infection via mucosal transmission [9,45]. From the initial side of infection HIS mice were 
also used to investigated HIV dissemination [46]. Interestingly, it was found that primarily 
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infected T cells disseminate HIV and if their egress from secondary lymphoid tissues was 
blocked, systematic HIV infection was inhibited. During this systematic infection also the viral 
quasispecies formation by mutations could be monitored [47]. Furthermore, HIS mice establish a 
latent HIV reservoir in resting CD4+ T cells [48-50]. Due to the recapitulation of these different 
aspects of HIV infection in humanized mice, therapeutic strategies against this retrovirus have 
been tested. These include anti-retroviral therapy (ART) [51,52], rectal microbicide treatment 
[53], anti-viral siRNA expression in T cells [54], CD4 and chemokine receptor knock-down or 
knock-out to reduce HIV infection [55,56] and adoptive transfer of HIV specific antibodies,  either 
cocktails of broadly neutralizing, toxin conjugated or expressed from viral vectors [47,57,58]. 
Thus, depending on the particular mouse model various aspects of primarily T cell infection can 
be modelled in HIS mice and the efficacy of therapeutic interventions can be tested in this 
setting.  
 Apart from HIV, human T cell leukemia virus (HTLV) – 1 infection was explored in HIS 
mice. In all instances infection was transferred by HTLV-1 harboring cells, either with in vitro 
infected CD34+ HPCs or with lethally irradiated infected T cells [59-61]. In all three studies 
expansions of HTLV-1 infected CD25+CD4+ T cells reminiscent of human adult T cell leukemia 
(ATL) were found. Therefore, HIS mice might serve as a valuable model to investigate HTLV-1 
induced pathology and tumor formation, even so the infection has to be done in a somewhat 
artificial way by intraperitoneal or intrahepatic transfer of infected cells. 
 
3.2. Flavivirus infections (dengue virus, HCV) 
Two members of the Flavivirus family have been investigated in HIS mice, namely dengue virus 
and hepatitis C virus (HCV). Dengue virus infection was performed by intraperitoneal, 
subcutaneous of intravenous injection into HIS mice [62-66]. In most instances dengue serotype 
2 viruses were used. Weight loss, skin rash, fever and thrombocytopenia were observed after 
infection. The most significant pathology associated with dengue virus infection in humans, 
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however, is dengue hemorrhagic fever after heterologous infection with another dengue virus 
serotype and it is thought that heterologous antibodies enhance infection by the second 
phenotype to cause this severe disease [67]. However, in HIS mice primarily IgM responses 
were so far detected after infection [64,66], and it remains unclear if these could mediate 
antibody mediated enhancement of heterologous dengue virus infection. Modelling of this 
disease would be the most valuable application of HIS mice to this viral infection. 
 While dengue virus infects leucocytes, possibly primarily myeloid cells [63], in HIS mice, 
establishing HCV infection in these models is much more difficult, because this virus infects 
primarily human hepatocytes. Moreover, it causes chronic liver inflammation that causes 
hepatocellular carcinoma in a subset of virus carriers.  Due to the liver tropism of this virus both 
human immune system components and human hepatocytes need to be engrafted into mice in 
order to study their interaction. This was performed in BRG mice, in which liver damage was 
induced, by transfer of hepatocyte precursors and HPCs [68]. These mice were then infected 
with HCV intravenously [69]. Both HCV induced liver damage and induction of HCV specific 
immune responses could be observed. However, human hepatocyte engraftment was limited in 
this study, and, therefore, the observed liver pathology requires further clarification. While this is 
a very interesting model the requirement of autologous hepatocyte precursors and HPCs for its 
generation might limit its broader application. 
  
3.3. Polyomavirus infections (JC) 
The polyomavirus John Cunningham (JC) virus has lately moved into the spotlight of the 
biomedical research community, because it was identified as the etiological agents of 
progressive multifocal leucoencephalopathy (PML), an inflammatory disease of the central 
nervous system (CNS), which is caused by JC virus reactivation after therapeutically limiting 
leucocyte access to the CNS, for example during natalizumab therapy against multiple sclerosis 
(MS) [70]. In order to understand JC virus specific immune control better, HIS mice were 
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intraperitoneally injected with JC virus [71]. This resulted in persistent infection and the virus 
could be detected in blood and urine for more than three months. While infection with a PML 
derived virus was more aggressive and led to more frequently detected viral titers and elevated 
IgM responses, no PML or CNS infection could be observed. Therefore, it remains unclear if HIS 
mice can be used to recapitulate PML pathogenesis. 
 
3.4. Orthomyxovirus infections (influenza) 
Another virus with mixed human and mouse tropism after infection of HIS mice is the 
orthomyxovirus influenza A virus. This segmented RNA virus causes lung infections and 
pandemics, especially when its genome segments rearrange to new combinations that have not, 
or not for a long time, been seen by the human population. Also its tropism in human cells was 
not characterized in detail, infection with live attenuated influenza A virus resulted in influenza 
antigen presentation on both CD1c+ and CD141+ dendritic cell (DC) subsets [72]. However, only 
CD1c+ DCs were able to prime influenza specific CD8+ T cell responses that can efficiently 
home back to epithelial tissues, including the lung. Moreover, influenza A virus infection elicited 
innate immune recognition in HIS mice, particularly when the lung myeloid compartment was 
better reconstituted after transgenic introduction of human GM-CSF and IL-3 into HIS mice [73]. 
Therefore, lung epithelial cell infection by influenza A virus can interact with reconstituted human 
immune system components in HIS mice, even so it remains unclear how many and which 
human leucocytes are directly infected with the virus under these conditions. 
 
4. Immune surveillance in mice with reconstituted human immune responses 
Overall, HIS mice develop within the three months after human CD34+ HPC injection that most 
investigators wait for reconstitution before experimentation, a fairly immature human immune 
system. Indeed the B cell compartment consists mainly of transitional and naïve B cells [74,75]. 
Furthermore, the NK cell compartment harbors CD56 negative cells and the frequency of killer 
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immunoglobulin like receptor (KIR) positive cells is only between 10 and 20% [27,76]. These 
characteristics are reminiscent of immune compartments in human cord blood, indicating that 
HIS mice have the immune systems of newborns. Accordingly, they are compromised in their 
ability to make humoral immune responses and primarily IgM antibodies against viruses can be 
found after infection. This was reported for huNSG, huBRG and BLT mice after HIV, HSV-2, 
adeno-, EBV, dengue and JC virus infection [16,40,43,62,66,77,78]. Consistent with these 
findings, the B cell areas of secondary lymphoid tissues of HIS mice do not show germinal 
center development [79], but can develop these structures after prolonged or repeated 
immunization [75,80]. In these structures, B cell differentiation beyond transitional and naïve B 
cells can be found and significant numbers of follicular helper T cells are present [75]. Also in 
line with a young immune system, NK cells efficiently restrict primary viral infections, like EBV, 
which are better handled in children than adults, while further differentiation by IL-15 injection 
compromises this innate immune control in HIS mice [27]. In general, cell mediated immune 
responses are much better developed in HIS mice than humoral immune responses. These can 
be initiated by DC populations, which are efficiently reconstituted in HIS mice and can be 
expanded by Flt3 ligand injection [79,81].  Both conventional and plasmacytoid human DCs 
respond to pathogen associated molecular patterns (PAMPs), which bind to toll-like receptors 
(TLRs), with the specificity that is expected from the more restricted and DC subset specific TLR 
expression in humans [79]. Human cytokines and chemokines that are produced by these DC 
populations as well as innate lymphocytes that rapidly respond to their activation can be 
measured one to three days after dengue virus infection, and 11 hours after TLR agonist 
administration [66,79]. IFN-2, IL-10 and CXCL10 correlated with the detected dengue viral 
titers [66]. Interestingly, mouse and human cytokines could be independently stimulated by TLR 
ligands, depending on the species specific TLR distribution [79].   Apart from the DCs’ ability to 
activate NK cell responses [76], they can also elicit CD4+ T cell responses [79] and presumably 
are involved in CD8+ T cell priming. Such CD8+ T cell responses have been reported during 
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EBV, HIV, adeno-, influenza and dengue virus infection of HIS mice [26,40,62,63,66,72,78,82-
84]. The presence of HLA class I transgenes or HLA expressing human thymic tissue seems to 
favor the development of CD8+ T cell responses during viral infections, which recognize 
dominant T cell epitopes defined in human virus carriers [26,62,82-84]. Mutational escape from 
these suggest that they are protective in vivo during HIV infection [83]. More directly, CD4+ and 
CD8+ T cells have been depleted with specific antibodies prior to some viral infections of HIS 
mice. These depletion studies indicate that during EBV infection both CD4+ and CD8+ T cells 
seem to contribute to immune control [26,85]. Furthermore, CD8+ T cells have been implicated in 
HIV and adenovirus specific immune control in HIS mice [40,86]. However, protective T cell 
specificities need to be defined in these human in vivo systems of viral infections in more detail 
in order to identify suitable antigens for vaccination. Overall, HIS mice seem to mount both 
innate and adaptive cellular immune responses to viral infections. While these are probably not 
able to control the respective pathogens as well as human individuals, they exert some degree 
of immune control and can therefore be interrogated for their protective functions in vivo. 
Moreover, additional genetic manipulations might be able to overcome some of the most 
significant short-comings of HIS mice, including secondary lymphoid tissue structure formation, 
cytokine and chemokine incompatibilities between mouse and man, and limited reconstitution of 
mucosal sites. Such improvements might then broaden the usefulness of HIS mice for vaccine 
development, allowing formulations to be tested also for the induction of humoral immune 
responses and protection at mucosal sites.    
 
5. Conclusions and outlook 
HIS mice constitute a valuable in vivo model for important human pathogens with a restricted 
tropism for the human hematopoietic lineage. They sustain infection with a number of these 
(HIV, EBV, HCMV, dengue and HTLV-1 for example). In addition, human cell-mediated immune 
responses can be studied in these models. However, many more hurdles have to be overcome 
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to develop HIS mice into robust in vivo model systems for human immune responses. The 
biggest is probably to obtain several genetically defined sources of human hematopoietic 
progenitor cells (HPCs) for their reconstitution. Induced pluripotent stem (iPS) cells bear great 
promise to become such sources [87], but efficient differentiation into HPCs for HIS 
reconstitution has not been achieved yet. The other short-comings, like deficient humoral 
immune responses and limited mucosal homing of reconstituted human immune system 
components are starting to be overcome [9,75], but require much more work to develop robust 
systems. Finally, more tools for human HPC manipulation need to be developed in order to 
manipulate and monitor human immune responses to viral infections more specifically in HIS 
mice. These include T cell receptor transgenes to allow the development of reporter T cell 
populations during viral infection, and recombinant viral vectors to knock-down, knock-out or 
overexpress certain genes in the developing hematopoietic lineage. Together with recombinant 
manipulation of the investigated human pathogens [27,28,88], the manipulation of human 
immune system components will generate potent preclinical models for relevant human 
diseases, which might yield results that can be more easily translated into the clinic. 
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Figure legend 
Figure 1: Human viral infections in mice with reconstituted human immune system 
components. NOD-scid c
-/- (NSG), NOD Rag1-/- c
-/- (NRG), BALB/c Rag2-/- c
-/- (BRG) or NOD-
scid with a human fetal thymus and liver organoid (LT) mice are injected with human HPCs for 
human immune system component reconstitution (HIS mice). Usually this reconstitution is 
allowed to proceed for three months. After analyzing reconstitution efficacy in the peripheral 
blood, HIS mice are infected with human viruses by intravenous, intraperitoneal or subcutaneous 
injection. The DNA viruses HBV, HSV-2, HCMV, EBV, KSHV and adenovirus, as well as the 
RNA viruses HIV, HTLV-1, dengue virus, HCV, JC virus and influenza A virus have been used 
for HIS mouse infections. These infections usually do not continue for more than 3 months. After 
this time period viral titers, virus induced pathology and primarily cell-mediated virus-specific 
immune responses are characterized. 
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Table 1. Viral pathogens of HIS mice.  
Virus Pathology in HIS mice Key reference1 
Hepatitis B virus (HBV) Liver disease [41] 
Herpes simplex virus 2 (HSV-2) Inflammation at mucosal infection site [16] 
Human cytomegalovirus (HCMV) 
GM-CSF mediated reactivation from 
myeloid cells 
[17] 
Epstein Barr virus (EBV) 
Tumor formation, hemophagocytic 
lymphohistiocytosis, erosive arthritis 
[89] 
Kaposi Sarcoma associated 
herpesvirus (KSHV) 
Persistent infection in B cells [39] 
Adenovirus Liver disease [40] 
Human immunodeficiency virus 
(HIV) 
CD4+ T cell depletion [43] 
Human T cell leukemia virus 1 
(HTLV-1) 
Akute T cell leukemia (ATL) like T cell 
expansions 
[59] 
Dengue virus Leucocyte infection [66] 
Hepatitis C virus (HCV) Liver disease [69] 
John Cunningham (JC) virus Persistent infection [71] 
Influenza A virus Lung infection [72] 
1 For clarity only one key reference has been listed 
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